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During the 13 years which have passed since the p53 protein
was first identified, studies of the p53 gene have gained in
scientific importance, leading to discoveries with major
clinical implications. Although originally classified as an
oncogene, more recent results from a number of studies have
established that the p53 gene exhibits properties conssistent
with a tumour suppressor gene. Mutations and deletions in
p53 have emerged as the most common genetic changes
found in cancer cells. The events leading to the classification
of p53 as a tumour suppressor gene are reviewed by Lane &
Benchimol, 1990.
The p53 gene includes five evolutionarily conserved
domains common to mammals, amphibians, birds and fish
(Soussi et al., 1990). Mutations seen in sporadic tumours are
largely missense mutations, clustering within conserved
domains II-V encompassing exons 5-8. In particular, at
least three mutational hot-spots at codons 175, 248 and 273
have emerged. Mutations at these hot-spots are characteristi-
cally transitions at CpG dinucleotides. Cancers originating
from various specific tissue sites differ with respect to the
distribution and frequency of mutations at these hot-spots.
Holstein et al., 1991 and Caron de Fromental and Soussi,
1992, have reviewed these patterns of mutations in human
cancers.
In November 1990 Malkin et al. reported germline muta-
tions in p53 in five families with the Li-Fraumeni syndrome
(LFS). LFS was first defined on the basis of familial clusters
of cancers in association with childhood soft tissue sarcomas.
In these families there was a high incidence of pre-meno-
pausal breast cancer, sarcomas and other cancers occurring
at unusually early ages in the relatives of the childhood
sarcoma cases (Li & Fraumeni, 1969). In 1988 Li et al.
published a study of 24 families with the syndrome. Among
these families, in addition to soft tissue sarcoma and early
onset breast cancer, osteosarcoma, brain tumours, leukaemia
and adrenocortical carcinoma also occurred to excess. The
mutations in LFS families reported by Malkin et al. (1990)
all occurred in exon 7 and were located between codons 245
and 258 within one of the evolutionarily conserved domains.
Shortly after, a case report of a sixth LFS family with a
germline mutation within the same stretch of codons was
published (Srivastava et al., 1990). These remarkable results
indicated that germline mutations in the p53 gene were re-
sponsible for the high incidence of cancers in these LFS
families. Furthermore, the restricted distribution of the germ-
line mutations implied that the association with LFS was
highly specific and supported the idea that different p53
alleles may have different properties (Levine et al., 1991).
Subsequent to the two original publications a number of
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groups around the world have been analysing cancer families
and individuals with cancer for the presence of germline p53
mutations. Reports from these groups are now beginning to
emerge.
We reported results of an analysis ofexon 7 in p53 in eight
families with typical features of LFS (Santibaniiez-Koref et al.,
1991). Mutations in exon 7 were found in only two of the
families. We have subsequently extended the analysis of these
families, plus an additional three families, to exons 4 through
8. A further three germline mutations were identified in exons
4, 5 and 6 respectively (Birch et al., in preparation). findings
from other groups include three studies of single families in
whom germline p53 mutations have been found. In two of
these the mutations were situated in exon 5 in a family with
typical LFS, and exon 7 in a family with early onset cancers
but where the pattern was not typical of LFS (Metzger et al.,
1991; Law et al., 1991). In the third family the proband with
breast cancer was found to have a mutation in exon 8. This
latter family is unusual because of the comparatively late
onset of the cancers (Prosser et al., 1992).
In a large series of patients with bone or soft tissue sar-
comas, eight patients with germline p53 mutations were
found. In five of these patients there was a previous family
history of cancer, but in three patients there was no known
previous significant family history. The mutations were of
diverse types and occurred in non-conserved regions in exons
4 and 6, as well as within the conserved domains in exons 7
and 8 (Toguchida et al., 1992). Further work from Stephen
Friend's group has identified germline p53 mutations in
pateints with multiple primary tumours as well as additional
LFS families. The mutations were found in exons 5-8. (Mal-
kin et al., 1992).
Codon 248 has emerged as a hot-spot for germline muta-
tions and examples of germline mutations at codons 175 and
273 have been found. The pattern of mutations that is now
evolving is more complex than was suggested by the original
reports, and includes a much wider spectrum of mutation
types that occur throughout the gene. Furthermore, it is clear
that germline p53 mutations are not restricted to families
with classic LFS. In addition, it is probable that p53 germline
mutations will not account for the high incidence ofcancer in
all families conforming to the clinical criteria for LFS,
although this has not yet been clearly demonstrated. Whether
or not particular mutations, or types of mutations, occur
with specific patterns of cancers within families has also yet
to be determined.
The discovery of germline p53 mutations which result in a
high risk of cancer in carriers of such mutations poses a
number of difficult clinical and ethical questions. As far as
clinical management is concerned, the first set of problems
arises because of uncertainty about the risks conferred by
germ-line p53 mutations. The spectrum of cancers associated
with such mutations is, as yet, ill defined, but is certainly
broad. The range of cancers so far reported in families with
germline p53 mutations include bone and soft tissue sar-
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comas, breast cancer, brain tumours, acute leukaemia,
melanoma, germ cell tumours, bladder cancer, and adreno-
cortical carcinoma. As more families are analysed this list of
associated cancers will probably be added to. Furthermore,
the age- and sex-specific risks for these cancers in individuals
with p53 mutations are not known.
General studies of cancer incidence in families with LFS
have demonstrated that the risk of cancer in members of
these families is highest at young ages. Above the age of 60
years the risk is no greater than that in the general popula-
tion (Birch et al., 1990; Garber et al., 1991). Since congenital
tumours have been observed in some affected families the
period of risk would appear to be between birth and 60 years
of age. Given this wide age at onset, and the fact that
possible cancers could potentially occur anywhere in the
body, devising an effective screening programme aimed at
early detection presents a very difficult if not impossible task.
However, even with present knowledge screening for cer-
tain cancers in particular age groups may be appropriate.
For example, the paediatric cancers associated with LFS
which have occurred in families with germline p53 mutations
are often abdominal, and regular ultrasound scans in young
children from these families may be of benefit. Various
screening modalities for breast cancer are available, but their
effectiveness in young women at high risk is unknown.
Nevertheless screening for breast cancer, which frequently
occurs at very young ages in these families, should perhaps
be considered. Whenever radiological procedures are used for
the purposes of screening, the apparent susceptibility of indi-
viduals from Li-Fraumeni families to the carcinogenic effects
of ionising radiation should be borne in mind. Although
doses from such procedures are low, screening may need to
be instituted at an early age and continue on a regular basis
for very many years.
Bearing in mind the limited potential for screening and
early detection of cancers in carriers of p53 germline muta-
tions, the questions of whether it is ethical to test asympto-
matic members of cancer families in whom such mutations
have been found must be addressed. At present the greatest
benefit that can be derived from testing is reassurance and
relief from anxiety in those family members found not to be
carriers of the mutation. There are other benefits, including
ability to plan education, future careers, and decisions on
marriage and child-bearing, taking into account the know-
ledge of cancer predisposition. For certain cancers in which
early detection is associated with a more favourable clinical
outcome, screening methods may be available.
These benefits should be weighed against a number of
disadvantages. Identification of carriers of germline muta-
tions which lead to increased risk of cancer may result in
discrimination at both social and economic levels. Employers,
for example, may be reluctant to appoint persons at high risk
of developing cancer, and it may be difficult to obtain life
insurance and mortgages, etc. The psychological effects of
belonging to families at high risk of cancer have not been
studied and are not understood. This is clearly an important
area which should be explored in relation to testing for
germline mutations in families with a high incidence of
cancer.
The only way to resolve these issues is to collect more data
on families with mutations, in order to build up information
on age-, site- and sex-specific risks, and to clarify whether
there are correlations between specific mutations and parti-
cular patterns of cancers. The families will need to be
managed in a careful and sensitive way, and psychological
assessment before and after testing ofasymptomatic members
is a necessity. A carefully planned long-term follow-up
schedule is also needed, in order to obtain data on the life
experiences of carriers of mutations, as well as data on
cancer incidence. By these means also it will be possible to
begin to collect data on the influence of other factors on the
risk of specific cancers, for example, the effects of reproduc-
tive factors on breast cancer risk in carriers of p53 germline
mutations. These aims can only be achieved within the con-
text of a multi-centre collaborative study. The Cancer Family
Study Group has set up a small working party to make
recommendations and draw up a protocol for testing for p53
germline mutations, including the clinical management and
follow-up of families. The group will make its recommenda-
tions later this year.
Families with germline p53 mutations are likely to be rare
in the population as a whole, but it can be expected that
other cancer susceptibility genes will be identified and charac-
terised in the not too distant future. It is therefore important
that the testing and management of families with p53 germ-
line mutations are carried out within the context of a col-
laborative interdisciplinary research protocol, in order to
provide a model for the future management of families with
mutations in other tumour suppressor genes. The scientific,
clinical and ethical challenges presented by the rare families
with p53 germline mutations must therefore be met in a
systematic way.
Jillian M. Birch is a Cancer Research Campaign Reader in
Oncology.
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